Suspected Antimonopoly Act Violations Over JCHO Tenders and Japan Fair Trade Commission Inspection
First written in FY2020-Q3. 7 of 9 entries say "Mitigated", first in FY2020. Latest entry: FY2026.
0 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「Provision for losses related to the Antimonopoly Act 2,233 —」
The provision for losses related to the Antimonopoly Act fell from ¥2,233 million at the end of the previous fiscal year to zero at the end of the current fiscal year. Payments related to the Antimonopoly Act of ¥1,781 million were recorded during the current fiscal year. - 2026-05-14MitigatedEarnings
「Change in provision for losses related to the Antimonopoly Act (△ indicates a decrease): △2,233」
The provision for losses related to the Antimonopoly Act was released from the ¥2.233 billion balance at the end of the previous fiscal year, and the statement of cash flows also reported ¥1.781 billion in payments related to the Antimonopoly Act. - FY2026-H1MitigatedAnnual report
「Provision for losses related to the Antimonopoly Act 2,233 —」
The balance of the provision for losses related to the Antimonopoly Act fell from ¥2,233 million at the end of the previous consolidated fiscal year to nil at the end of the current interim consolidated accounting period. In addition, ¥1,573 million was recorded as payments related to the Antimonopoly Act. The changes in these accounting balances and payments were disclosed, but the text did not specify a direct connection with any individual matter. - FY2022MitigatedAnnual report
「On 30 March 2022, the Japan Fair Trade Commission announced that it had issued a cease-and-desist order and a surcharge payment order to the companies participating in bids for pharmaceuticals ordered by the Japan Community Health care Organization (JCHO) for conduct in violation of Article 3 of the Antimonopoly Act, which prohibits unreasonable restraint of trade. Mediceo Corporation (Chuo-ku, Tokyo), a wholly owned consolidated subsidiary of the Company, was subject to an on-site inspection by the Japan Fair Trade Commission in November 2019 and a search by the Tokyo District Public Prosecutors Office and an on-site inspection by the Japan Fair Trade Commission in October 2020 in connection with this matter. However, Mediceo applied for leniency under the surcharge reduction and immunity program, voluntarily reported its past violations, and fully cooperated with the Commission's investigation. As a result, it did not receive either a cease-and-desist order or a surcharge payment order.」
Although the JCHO bidding matter progressed to the Japan Fair Trade Commission's announcement of orders, the disclosure stated that Mediceo had not received either a cease-and-desist order or a surcharge payment order because it applied for leniency, made a voluntary report, and cooperated with the investigation. - FY2021MitigatedAnnual report
「The Company takes this matter very seriously. At a meeting of the Board of Directors held in January 2021, it resolved to review all operations, once again ensure thorough compliance, and reduce executive compensation.」
In response to the matter involving the JCHO bidding, the Company reviewed all operations, ensured thorough compliance, and reduced executive compensation. - FY2021-Q3MitigatedAnnual report
「We take this situation very seriously and have responded sincerely. At a meeting of the Board of Directors held on 29 January 2021, the company resolved to ensure thorough compliance once again and to reduce executive remuneration.」
The Board of Directors resolved measures in response to the risks associated with the search and on-site inspection concerning the JCHO bidding, including ensuring compliance and reducing executive compensation. There was no disclosure that the investigation and inspection themselves had ended. - FY2021-Q2WorsenedAnnual report
「Mediceo Corporation, a wholly owned consolidated subsidiary of the Company, was subject to a search by the Tokyo District Public Prosecutors Office and an on-site inspection by the Japan Fair Trade Commission in October 2020 on suspicion of violating the Antimonopoly Act in connection with bids for pharmaceuticals ordered by the Japan Community Health care Organization (JCHO). Together with Mediceo Corporation, the Company takes this matter very seriously and is fully cooperating with the authorities' investigation and inquiry. If any material matter requiring disclosure arises in the future, we will promptly disclose it.」
Regarding the matter involving the JCHO bidding, the disclosure stated that, in addition to the Japan Fair Trade Commission's inspection, the Company had also been subject to a search by the Tokyo District Public Prosecutors Office, and indicated its policy of fully cooperating with the authorities and making additional disclosures. - FY2020MitigatedAnnual report
「Going forward, we will also work to ensure even stricter compliance with laws and regulations throughout the Group and to strengthen our internal controls.」
In connection with the Japan Fair Trade Commission's investigation into the JCHO bidding, the Company set out a response policy of strengthening legal compliance and internal controls, in addition to cooperating with the investigation. - FY2020-Q3First statedAnnual report
「Mediceo Corporation, a wholly owned consolidated subsidiary of the Company, was subject to an on-site inspection by the Japan Fair Trade Commission in November 2019 on suspicion of violating the Antimonopoly Act in connection with bids for pharmaceuticals ordered by the Japan Community Health care Organization (JCHO). Together with Mediceo Corporation, the Company takes this matter very seriously and is fully cooperating with the Japan Fair Trade Commission's inspection.」
This was the first disclosure that Mediceo had been subject to an on-site inspection by the Japan Fair Trade Commission on suspicion of violating the Antimonopoly Act in connection with bids for pharmaceuticals ordered by JCHO. The Company did not assert that a violation had occurred and stated that it would fully cooperate with the inspection.